Oslo, 12 September 2022 - Targovax ASA announces that members of its executive
management team are invited to present at upcoming conferences:

H.C. Wainwright 24th Annual Global Investment Conference, virtual
Date: 12 September 2022
Presenter: Erik Digman Wiklund, CEO
Time: Presentation available online from 07:00 EDT / 13:00 CEST

RAS Targeted Drug development summit, Boston
Date: 28 September 2022
Presenter: Lone Ottesen, CMO
Time: 12:30 EDT / 18:30 CEST

Immuno-Oncology Summit, Boston
Date: 14 October 2022
Presenter: Erik Digman Wiklund, CEO
Time: 11:45 EDT / 17:45 CEST

World Vaccine Congress Europe, Barcelona
Date: 11-14 October 2022
Presenter: Lubor Gaal, CFO
Time: TBD

***

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@targovax.com

Renate Birkeli, Investor Relations
Phone: +47 922 61 624
Email: renate.birkeli@targovax.com

Media enquires:
Andreas Tinglum - Corporate Communications (Norway)
Phone: +47 9300 1773
Email: andreas.tinglum@corpcom.no

About Targovax

Activating the patient's immune system to fight cancer

Targovax (OSE:TRVX) is a clinical stage immuno-oncology company developing
immune activators to target hard-to-treat solid tumors. Targovax's focus is to
activate the patient's immune system to fight cancer, and thereby bring benefit
to cancer patients with few available treatment alternatives. Targovax is
assessing its product candidates in different cancer indications, including
melanoma, mesothelioma and multiple myeloma, and has demonstrated a favorable
safety and tolerability profile.

Targovax's lead clinical candidate, ONCOS-102, is a genetically modified
oncolytic adenovirus, which has been engineered to selectively infect cancer
cells and activate the immune system against the tumor. Following very
encouraging clinical data in several indications, both as monotherapy and in
combinations, ONCOS-102 is progressing into a randomized phase 2 trial in
melanoma patients resistant to PD-1 checkpoint inhibitor treatment.

Building on successful studies demonstrating clinical efficacy and providing
deep mechanistic insights, the Targovax platform is being expanded into delivery
of circular RNA (circRNA). In addition, Targovax has a KRAS immunotherapy
program, with lead cancer vaccine candidate, TG01, due to enter the clinic in
the second half of 2022. This provides Targovax with a rich pipeline of
innovative future immunotherapy product candidates to follow ONCOS-102.